107篇中國論文涉嫌造假 遭國外期刊撤稿

Tumor Biology, a Springer journal, retracted 107 articles in a single notice last Thursday.

在上週四的一則通知中，斯普林格出版社旗下的期刊《腫瘤生物學》宣佈撤銷107篇論文。

The supposedly peer-reviewed papers did not appropriately go through the peer-review process, the publisher and editor of the paper writes in a terse note accompanying the list of discredited studies.

論文出版社以及編輯用簡潔的口吻寫道，本應經過同行評議的這些論文，並沒有正規地完成這一流程。隨附的還有疑似論文的名單。

"After a thorough investigation we have strong reason to believe that the peer review process was compromised," they write.

他們寫道：“在全面調查後，我們有足夠的理由相信同行評議是造假的。”

The papers are predominantly authored by scientists from China, and were published from 2012 up until last year. The subjects span from the impacts of smoking on cancer, to gene-specific effects on tumors.

這些論文的作者主要是來自中國的科學家，發表時間爲2012年至去年。論文主題涵蓋了抽菸對於癌症的影響、基因特異性對於腫瘤的影響。

The site Sixth Tone first reported on the massive retraction. One of Springer's editorial directors told the Chinese media outlet that the studies had been submitted with suggestions from reviewers with real names – but with fabricated email addresses.

《第六聲》網站首先報道了此次大規模撤稿事件。斯普林格出版社的一名編輯主任向中國的媒體透露，這些論文提交時附有實名評議員的意見，但是電子郵件地址是僞造的。

Springer is not the first major publisher to discover widespread peer review problems prompting mass retractions.

斯普林格並非是第一家通過發現大範圍同行評議問題從而引起大規模撤稿的重要出版社。

BioMed Central retracted 43 papers in one action in November 2014, and Hindawi Publishing Corporation announced in 2015 that three editors had "subverted" the entire editorial process in publishing 32 papers.

2014年11月，BioMed Central出版社曾一次性撤銷過43篇論文；另外，Hindawi出版社於2015年宣佈，三名編輯“破壞了”32篇論文發佈的整個編輯過程。